1 |
Liu FB, Lunsford EP, Tong JL, et al. Real-time monitoring of tumorigenesis,dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex[J]. PLoS One, 2012, 7(6): e38589.
|
2 |
刘春平,顾莹莹. 肺淋巴管平滑肌瘤病的临床病理学分析[J]. 诊断病理学杂志,2022, 29(11): 1037-1040, 1048.
|
3 |
赵天明,倪吉祥. 肺淋巴管平滑肌瘤病1例[J/CD]. 中华肺部疾病杂志(电子版), 2017. 10(4): 501-503.
|
4 |
陈雪芬,邓静敏. 肺淋巴管肌瘤病治疗的研究进展[J/CD]. 中华临床医师杂志(电子版), 2021, 15(7): 556-560.
|
5 |
Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2017, 196(10): 1337-1348.
|
6 |
Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference[J]. Pediatr Neurol, 2013, 49(4): 255-265.
|
7 |
Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference[J]. Pediatr Neurol, 2013, 49(4): 243-254.
|
8 |
中国抗癌协会泌尿男生殖系肿瘤专业委员会结节性硬化协作组. 结节性硬化症相关肾血管平滑肌脂肪瘤诊疗与管理专家共识[J]. 中国癌症杂志,2020, 30(1): 70-78.
|
9 |
Revilla-López E, Ruiz de Miguel V, López-Meseguer M, et al. Lymphangioleiomyomatosis: Searching for potential biomarkers[J]. Front Med (Lausanne), 2023, 10: 1079317.
|
10 |
Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth[J]. Nat Cell Biol, 2019, 21(1): 63-71.
|
11 |
Evans JF, Obraztsova K, Lin SM, et al. CrossTORC and WNTegration in disease: Focus on lymphangioleiomyomatosis[J]. Int J Mol Sci, 2021, 22(5): 2233.
|
12 |
Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease[J]. Nat Rev Mol Cell Biol, 2020, 21(4): 183-203.
|
13 |
Tee AR. The target of rapamycin and mechanisms of cell growth[J]. Int J Mol Sci, 2018, 19(3): 880.
|
14 |
Brakemeier S, Grohé C, Bachmann F, et al. Sporadic lymphangioleiomyomatosis (sLAM) and tuberous sclerosis complex (TSC)-pulmonary manifestations[J]. Pneumologie, 2017, 71(2): 86-95.
|
15 |
Hirose M, Matsumuro A, Arai T, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis[J]. PLoS One, 2019,14(2): e0212776.
|
16 |
He J, Ma J, Ren B, et al. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway[J]. Semin Arthritis Rheum, 2020, 50(2): 314-320.
|
17 |
姜永浩,张 蕾,张嘉铖. 不稳定性心绞痛合并干燥综合征及肺淋巴管肌瘤病1例并文献复习[J]. 重庆医学,2023, 52(4): 638-640.
|
18 |
Lu Y, Liu X, Zhang E, et al. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells[J]. PLoS One, 2020, 15(2): e0228894.
|
19 |
Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis[J]. Lymphat Res Biol, 2006, 4(3): 143-152.
|
20 |
Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement[J]. Chest, 2009,135(5): 1293-1300.
|
21 |
Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity[J]. Nat Rev Immunol, 2013, 13(9): 649-665.
|
22 |
McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis diagnosis and management[J]. Am J Respir Crit Care Med, 2016, 194(6): 748-761.
|
23 |
Ancona S, Orpianesi E, Bernardelli C, et al. Differential modulation of matrix metalloproteinases-2 and-7 in LAM/TSC cells[J]. Biomedicines, 2021, 9(12): 1760.
|
24 |
Dong X, Jin L, Wang A, et al. A Systematic review of lymphangioleiomyomatosis on diagnosis and molecular mechanism[J]. Biomed Res Int, 2021, 2021: 6612776.
|
25 |
张龙举,梁 毅,钟小宁,等. 国内三十余年肺淋巴管肌瘤病130例临床与病理文献复习分析[J]. 中国全科医学,2015, 18(3): 329-334.
|
26 |
宋留存,李富建,秦雪青. CT诊断胸部弥漫性疾病的临床应用意义评析[J]. 中国CT和MRI杂志,2017, 15(6): 63-65.
|
27 |
贾永军,于 楠,杨创勃,等. 基于模型的迭代重建在改善胸部低剂量CT评价早期周围型肺癌中的价值[J]. 中国医学影像学杂志,2019, 27(9): 682-686.
|
28 |
朱慧媛,张 莲,王亚丽,等. 超高分辨率CT靶扫描对肺结节的诊断价值[J]. 第二军医大学学报,2017, 38(9): 1165-1170.
|
29 |
赵金勇,曹世文. 高分辨CT对肺淋巴管平滑肌瘤病与特发性肺间质纤维化的鉴别诊断意义[J]. 医学影像学杂志,2016, 26(2): 359-361.
|
30 |
He F, Zhong J, Chai R, et al. A pulmonary lymphangioleiomyomatosis with multi-site angiomyolipoma: a case report[J]. Transl Cancer Res, 2022, 11(7): 2449-2456.
|
31 |
中华医学会呼吸病学分会间质性肺疾病学组,淋巴管肌瘤病共识专家组,中国医学科学院罕见病研究中心,等. 西罗莫司治疗淋巴管肌瘤病专家共识(2018)[J]. 中华结核和呼吸杂志,2019, 42(2): 92-97.
|
32 |
Medeiros V, Gonçalves de Lima J, Rosa C, et al. Physiotherapy in lymphangioleiomyomatosis: a systematic review[J]. Ann Med, 2022, 54(1): 2744-2751.
|
33 |
Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for[J]. Eur Respir Rev, 2011, 20(119): 34-44.
|
34 |
Schneider BS, Maimon J, Golub LM, et al. Tetracyclines inhibit intracellular muscle proteolysis in vitro[J]. Biochem Biophys Res Commun, 1992, 188(2): 767-772.
|
35 |
Ginns LC, Roberts DH, Mark EJ, et al. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline[J]. Chest, 2003, 124(5): 2017-2022.
|
36 |
Yoon HY, Kim HJ, Song JW. Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis[J]. Respir Res, 2022, 23(1): 158.
|